Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,010 across all filing types
Latest filing 2024-09-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
第六届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 14th meeting of the 6th Board of Directors of Kangzhi Pharmaceutical Co., Ltd. It details voting results on stock incentive plans and related matters. The document is short (1173 characters) and primarily reports board decisions rather than providing detailed financial data or full reports. It also references other announcements for more details. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. It is not an annual report, audit report, or earnings release, nor is it a regulatory filing or report publication announcement. Therefore, the classification is MANG with high confidence.
2024-09-25 Chinese
监事会关于2023年限制性股票激励计划第一个归属期归属名单的核查意见
Share Issue/Capital Change Classification · 95% confidence The document is a formal opinion from the Supervisory Board regarding the verification of the first vesting period list under the 2023 restricted stock incentive plan. It discusses compliance with laws and regulations, the legitimacy of the incentive recipients, and the number of shares vested. The document is an announcement related to a stock incentive plan and the approval of share vesting, which aligns with announcements about share issues or capital changes. It is not a full report, financial statement, or management discussion, but rather a formal announcement of a capital-related event. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length is short and focused on this specific announcement, supporting this classification with high confidence.
2024-09-25 Chinese
关于作废处理部分限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from 康芝药业股份有限公司 regarding the cancellation of certain restricted stocks under the 2023 restricted stock incentive plan. It details the decision-making process, reasons for cancellation, number of shares affected, and legal and supervisory opinions. The document is relatively short (2151 characters) and focuses on a specific corporate action related to stock incentives. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory filing or certification. The content fits best with announcements related to share issues or capital changes, specifically the cancellation of restricted stock awards, which is a capital change event. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-09-25 Chinese
北京中伦（海口）律师事务所关于康芝药业股份有限公司 2023 年限制性股票激励计划第一个归属期归属条件成就及部分限制性股票作废事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the achievement of vesting conditions and partial cancellation of restricted stock under a 2023 restricted stock incentive plan of a company. It references relevant laws, regulatory rules, board and shareholder approvals, and details about the stock incentive plan's vesting period, conditions, and affected individuals. The document is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to a stock incentive plan. It is not a report publication announcement or a certification letter but a standalone legal opinion. This type of document fits best under the category of Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and stock incentive plans, and does not fit other more specific categories like Remuneration Information or Board/Management Information. The document length (6524 characters) and content confirm it is a substantive legal opinion rather than a brief announcement or a full annual/interim report.
2024-09-25 Chinese
关于遭受台风灾害影响的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the impact of a typhoon disaster on the company's production base, detailing damage, estimated losses, and recovery efforts. It does not contain financial statements, audit results, or detailed financial data. It is a regulatory announcement informing investors about a significant event affecting operations and potential financial impact, but it is not a full financial report or earnings release. The document length is short (965 characters), and it is a standalone announcement about a specific event. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2024-09-11 Chinese
关于公司控股股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the controlling shareholder of the company 康芝药业股份有限公司. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company stock, the pledge terms, and assurances about the impact on company operations and governance. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory disclosure about share pledging, which is a capital/financing activity. It is not a full financial report, earnings release, or management report. The document length is 2286 characters, which is relatively short and typical for an announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-09-03 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.